The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy

PLoS One. 2010 Apr 2;5(4):e10014. doi: 10.1371/journal.pone.0010014.

Abstract

Background: Aggregation and misfolded alpha-synuclein is thought to be central in the pathogenesis of Parkinson's disease (PD). Heat-shock proteins (HSPs) that are involved in refolding and degradation processes could lower the aggregate load of alpha-synuclein and thus be beneficial in alpha-synucleinopathies.

Methodology/principal findings: We co-overexpressed human A53T point-mutated alpha-synuclein and human HSP70 in mice, both under the control of Thy1 regulatory sequences. Behavior read-outs showed no beneficial effect of HSP70 expression in mice. In contrast, motor coordination, grip strength and weight were even worse in the alpha-synucleinopathy model in the presence of HSP70 overexpression. Biochemical analyses revealed no differences in alpha-synuclein oligomers/aggregates, truncations and phosphorylation levels and alpha-synuclein localization was unchanged in immunostainings.

Conclusion/significance: Overexpressing HSP70 in a mouse model of alpha-synucleinopathy did not lower the toxic load of alpha-synuclein species and had no beneficial effect on alpha-synuclein-related motor deficits.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Body Weight
  • Disease Models, Animal
  • Genetic Therapy
  • HSP70 Heat-Shock Proteins / administration & dosage
  • HSP70 Heat-Shock Proteins / genetics
  • HSP70 Heat-Shock Proteins / therapeutic use*
  • Hand Strength
  • Humans
  • Mice
  • Mice, Transgenic
  • Motor Activity
  • Parkinson Disease / pathology
  • Parkinson Disease / therapy*
  • Point Mutation
  • Protein Folding
  • Protein Multimerization
  • Treatment Failure
  • alpha-Synuclein / administration & dosage
  • alpha-Synuclein / adverse effects*
  • alpha-Synuclein / genetics

Substances

  • HSP70 Heat-Shock Proteins
  • alpha-Synuclein